Hypersensitivity reactions to the taxanes paclitaxel and docetaxel

Clinical Drug Investigation

Volumn 14, Issue 5, 1997, Pages 418-427

  Panday, Vinodh R Nannan ^a,b   Huizing, Manon T ^a,b,c   Ten Bokkel Huinink, Wim W ^a   Vermorken, Jan B ^c   Beijnen, Jos H ^a,b,d  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DOCETAXEL; PACLITAXEL;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MALE; PREMEDICATION; PRIORITY JOURNAL;

EID: 0030664970     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714050-00011     Document Type: Article

References (46)

1. Schiff PB, Fant J, Horwitz, SB. Promotion of microtubule assembly in Vitro by taxol. Nature 1979; 277: 665-7
2. Wani MC, Taylor HL, Wall ME. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-7
3. Rowinsky EK, Onetto N, Canetta R, et al. Taxol, the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646-62
4. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1005-14
5. Donehower RC, Rowinsky EK. An overview of Taxol (paclitaxel) in the USA. Review. Cancer Treat Rev 1993; 19 Suppl. C: 63-78
6. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704-12
7. Onetto N, Canetta R, Winograd B, et al. Overview of Taxol safety. Monogr Natl Cancer Inst 1993; 15: 131-9
8. Arbuck SG, Strauss H, Rowinsky EK, et al. A reassessment of cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993; 15: 117-30
9. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8
10. Kris MG, O'Connell JP, Gralla RJ, et al. Phase I trial of taxol given as a 3h infusion every 21 days. Cancer Treat Rep 1986; 70: 605-7
11. National Cancer Institute, Bethesda, MD, Division of Cancer Treatment. Clinical Brochure: Taxol (NSC-125973), 1991
12. Greenberger PA, Patterson R, Simon R, et al. Pretreatment of high-risk patients requiring radiographic contrast media studies. J Allergy Clin Immunol 1981; 67: 185-7
13. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19: 458-77
14. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20 Suppl. 3: 1-15
15. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose vs low-dose and long vs short infusion. J Clin Oncol 1994; 12: 2654-66
16. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): A semi-synthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91
17. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55
18. Verweij J, Clavel M, Chevalier B. Paclitaxel and docetaxel, not simply two of a kind. Ann Oncol 1994; 5: 495-505
19. Wanders J, Schrijvers D, Bruntsch U, et al. The EORTC-ECTG experience with acute hypersensitivity reactions (HSR) in Taxotere studies [abstract 94]. Proc Am Soc Clin Oncol 1993; 12: 73
20. Fumoleau P, Chevalier B, Kerbrat P, et al. Current status of Taxotere as a new treatment in breast cancer. Breast Cancer Res Treat 1994; 33: 39-46
21. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase 11 study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996; 14: 422-8
22. Peereboom D, Donehower RC, Eisenhauer EA, et al. Successful retreatment with Taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11: 885-90
23. Schrijvers D, Wanders J, Dirix L, et al. Coping with the toxicities of docetaxel (Taxotere). Ann Oncol 1993; 4: 610-1
24. Del Priore G, Smith P, Warshal DP, et al. Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions. Gynecol Oncol 1995; 56: 316-8
25. Giaccone G, Huizing MT, Postmus PE, et al. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer, an interim report. Semin Oncol 1995; 22 (4 Suppl. 9): 78-82
26. Huizing MT, Rosing H, Vermorken JB, et al. Increased paclitaxel and metabolism levels in patients with altered hepatic function [abstract 379]. Proc Am Soc Clin Oncol 1996; 15: 182
27. Giaccone G, Huizing MT, Ten Bokkel Huinink WW, et al. Preliminary results of two dose-finding studies of paclitaxel and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort. Semin Oncol 1994; 21 (5 Suppl. 8): 34-8
28. Vermorken JB, Ten Bokkel Huinink WW, Mandjes IA, et al. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Centre effort. Semin Oncol 1995; 22 (4 Suppl. 8): 16-22
29. Ten Bokkel Huinink WW, Dubbelman R, Hiemstra A, et al. Phase I study of docetaxel alternating with epirubicin and cyclofosfamide in an escalated and accelerated schedule by the concomitant use of lenograstim [abstract 299]. Proc Am Soc Clin Oncol 1996; 15: 141
30. Westermann AM, Ten Bokkel Huinink WW, Rodenhuis S. Successful docetaxel rechallenge with eromoglycate after major sensitivity reactions. Ann Oncol 1996; 7: 104
31. Lasser EC, Walters A, Reuter SR, et al. Histamine release by contrast media. Radiology 1971; 100: 683-6
32. Terr AI. Anaphylaxis and urticaria. In: Stites DP, Terr AI, Parslow TG, editors. Basic and clinical immunology. 8th ed. Norwalk, CT: Appleton and Lange. 1994: 347-56
33. Dorr RT. Pharmacology and toxicology of Cremophor EL. Ann Pharmacother 1994; 28: S11-S34
34. Theis JGW, Liau-Chu M, Chan HSL, et al. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 1995; 13: 2508-16
35. Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7: 63-7
36. Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Review. Kidney Intern Suppl. 1992; 37: S34-S37
37. Weir MR, Klassen DK, Shen SY, et al. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics and urine prostaglandin production of healthy humans. Transplantation 1990; 49: 41-7
38. Piccart MJ, Gore M, Ten Bokkel Huinink WW, et al. Taxotere, an active new drug for the treatment of advanced ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81
39. Mertens WC, Eisenhauer EA, Solivet J, et al. Docetaxel in advanced renal carcinoma. A Phase II trial of the National Cancer Institute ot Canada Clinical Trials Group. Ann Oncol 1994; 5: 185-7
40. Donehower RC, Rowinsky EK, Grochow LB, et al. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71: 1171-7
41. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1430-5
42. Solimando Jr. DA, Phillips ET, Weiss RB, et al. Hypertensive reactions associated with paclitaxel. Cancer Invest 1996; 14: 340-2
43. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9
44. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14: 1877-84
45. Sharma A, Straubinger RM. Novel Taxol formulations: preparation of Taxol containing liposomes. Pharmaceutical Res 1994; 11: 889-96
46. Meerum Terwogt J, Nuijen B, Ten Bokkel Huinink WW et al. Alternative formulations of paclitaxel. Cancer Treat Rev 1997; 23: 87-96